Comparison between Ceigall India IPO and Emcure Pharmaceuticals IPO.
Ceigall India IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Emcure Pharmaceuticals IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Ceigall India IPO is up to ₹1,252.66 Cr whereas the issue size of the Emcure Pharmaceuticals IPO is up to ₹1,952.03 Cr. The final issue price of Ceigall India IPO is ₹401.00 per share and of Emcure Pharmaceuticals IPO is ₹1,008.00 per share.
| Ceigall India IPO | Emcure Pharmaceuticals IPO | |
|---|---|---|
| Face Value | ₹5 per share | ₹10 per share |
| Issue Price (Lower) | ₹380.00 per share | ₹960.00 per share |
| Issue Price (Upper) | ₹401.00 per share | ₹1,008.00 per share |
| Issue Price (Final) | ₹401.00 per share | ₹1,008.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹38.00 per share | ₹90.00 per share |
| Market Lot Size | 37 shares | 14 shares |
| Fresh Issue Size | 1,70,68,861 shares | 79,46,231 shares |
| Fresh Issue Size (Amount) | up to ₹684.35 Cr | up to ₹800.58 Cr |
| OFS Issue Size | 1,41,74,840 shares | 1,14,28,839 shares |
| OFS Issue Size (Amount) | up to ₹568.32 Cr | up to ₹1,151.45 Cr |
| Issue Size Total | 3,12,43,701 shares | 1,93,75,070 shares |
| Issue Size Total (Amount) | up to ₹1,252.66 Cr | up to ₹1,952.03 Cr |
Ceigall India IPO opens on Aug 01, 2024, while Emcure Pharmaceuticals IPO opens on Jul 03, 2024. The closing date of Ceigall India IPO and Emcure Pharmaceuticals IPO is Aug 05, 2024, and Jul 05, 2024, respectively.
| Ceigall India IPO | Emcure Pharmaceuticals IPO | |
|---|---|---|
| Anchor Bid Date | Jul 31, 2024 | Jul 02, 2024 |
| Issue Open | Aug 01, 2024 | Jul 03, 2024 |
| Issue Close | Aug 05, 2024 | Jul 05, 2024 |
| Basis Of Allotment (Tentative) | Aug 06, 2024 | Jul 08, 2024 |
| Initiation of Refunds (Tentative) | Aug 07, 2024 | Jul 09, 2024 |
| Credit of Share (Tentative) | Aug 07, 2024 | Jul 09, 2024 |
| Listing date (Tentative) | Aug 08, 2024 | Jul 10, 2024 |
| Anchor Lockin End date 1 | Sep 04, 2024 | Aug 07, 2024 |
| Anchor Lockin End date 2 | Nov 03, 2024 | Oct 06, 2024 |
Ceigall India IPO P/E ratio is 20.67, as compared to Emcure Pharmaceuticals IPO P/E ratio of 34.55.
| Ceigall India IPO | Emcure Pharmaceuticals IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 99.99 | 83.21 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 82.06 | 78.08 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 20.67 | 34.55 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹6985.41 Cr. | ₹19029.89 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 33.57% | 16.90% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 31.98% | 19.37% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.17 | 0.67 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹19.40 | ₹29.17 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 33.57% | 16.87% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Ceigall India IPO Retail Individual Investors (RII) are offered 1,09,16,012 shares while in Emcure Pharmaceuticals IPO retail investors are offered 1,09,16,012 shares. Qualified Institutional Buyers (QIB) are offered 62,37,721 shares in Ceigall India IPO and 38,53,234 shares in Emcure Pharmaceuticals IPO.
| Ceigall India IPO | Emcure Pharmaceuticals IPO | |
|---|---|---|
| Anchor Investor Reservation | 93,56,581 shares | 57,79,850 shares |
| Market Maker Reservation | ||
| QIB | 62,37,721 shares | 38,53,234 shares |
| NII | 46,78,291 shares | 28,89,926 shares |
| RII | 1,09,16,012 shares | 67,43,160 shares |
| Employee | 55,096 shares | 1,08,900 shares |
| Others | ||
| Total | 3,12,43,701 shares | 1,93,75,070 shares |
Ceigall India IPO subscribed 14.01x in total, whereas Emcure Pharmaceuticals IPO subscribed 67.87x.
| Ceigall India IPO | Emcure Pharmaceuticals IPO | |
|---|---|---|
| QIB (times) | 31.26x | 191.24x |
| NII (times) | 14.83x | 49.32x |
| Big NII (times) | 16.28x | 54.90x |
| Small NII (times) | 11.92x | 38.16x |
| RII (times) | 3.82x | 7.36x |
| Employee (times) | 11.84x | 8.81x |
| Other (times) | ||
| Total (times) | 14.01x | 67.87x |
